This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Typical atrialflutter commonly occurs in patients with atrial fibrillation (AF). Limited information exists regarding the effects of concurrent atrialflutter on the long-term outcomes of rhythm control. The data were obtained from a multicenter registry of cryoballoon ablation for AF ( n = 2,689).
Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablate heart tissue – will be compared to outcomes following use of anti-arrhythmic drug (AAD) therapy, which is commonly prescribed for patients living with persistent AF. The company now anticipates U.S.
Atypical AtrialFlutter (AAFL) prevalence is increasing due to the escalating Atrial Fibrillation (AF) ablations and cardiac surgeries. We wanted to explore the outcome of the AAFL ablation, considering the recent changes in mapping and ablation.
Idiopathic atypical (non-cavotricupid isthmus [CTI]-dependent) atrialflutter (IAAFL) may be seen in patients without structural heart disease and without previous cardiac surgery or ablation.
Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) is often accompanied by atrial fibrillation (AF), atrialflutter (AFL), and atrial tachycardia (AT), which are difficult to control because beta-blockers and antiarrhythmic drugs can worsen heart failure (HF).
Background The value of empirical superior vena cava isolation (SVCI) following pulmonary vein isolation (PVI) to improve the efficacy of radiofrequency catheter ablation (RFCA) for paroxysmal atrial fibrillation (PAF) remains controversial. RFCA was guided by quantitative AI in both groups. vs 81.5%, p=0.02). 95% CI 0.19
Ablation of isthmus-dependent atrialflutter with interventional CMR has demonstrated its efficacy and safety in the initial phase for achieving bidirectional block. However, limited long-term follow-up data exist for these patients.
Cheng and Zhang to our paper1, we note that despite ARVC being a relatively uncommon cardiomyopathy, we uniquely report on a large clinical experience with very long-term follow-up after VT ablation and confirm a high incidence of atrialflutter (AFL) and the effectiveness and low risk of catheter ablation of AFL.
We performed a systematic review investigating the effect of rurality on AF care and outcomes in the United States. PubMed was queried for entries on AF and rurality: (atrial fibrillation OR atrialflutter) AND (rural OR urban OR rurality OR metro OR metropolitan) AND (united states OR US OR U.S.)
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech , today announced European CE mark approval of the VARIPULSE Platform for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation ( AF ) using pulsed field ablation (PFA).
Recurrence rates after catheter ablation in these patients are high. Demographic, clinical, and outcome variables over 5 years were compared between patients with and without SVT recurrence.Results:Mean age of 25 patients (56% male) at time of SVT ablation was 31.5 ± 7.2 Ablation success rate was 92%.
Abstract Background Dofetilide is a class III antiarrhythmic agent approved for the treatment of atrial fibrillation and atrialflutter. Prior catheter ablation had been performed in 33 patients (41%). A80% decrease in PVC burden was defined as a satisfactory response. An ICD was present in 72 patients (89%).
The PulseSelect Pulsed Field Ablation System, which was FDA approved in December 2023, offers physicians a safe, single-shot solution for pulmonary vein isolation (PVI) while the Affera Sphere-9 catheter enables physician treatment flexibility with its wide area focal design and 9mm lattice tip that can used with an 8.5Fr sheath.
ABSTRACT Typical atrialflutter (AFL), defined as cavotricuspid isthmus (CTI)-dependent macro-re-entrant atrial tachycardia, often causes debilitating symptoms, and is associated with increased incidence of atrial fibrillation, stroke, heart failure, and death.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
64 
Let's personalize your content